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Cardiac disease is a cause of maternal mortality in developed and 
developing countries globally. In the UK, the Confidential Enquiry 
into Maternal and Child Health (CEMACH) showed that the overall 
rate of mortality from cardiac disease rose from 7.3/1 000 000 
births in 1982 - 1984 to 22.7/1 000 000 births in 2009 - 2011.[1,2] The 
institutional maternal mortality rate (iMMR) for cardiac disease 
was 2/100 000 during 2012 - 2014.[2] The major part of this increase 
is attributable to acquired heart disease.[1]
In South Africa (SA), according to the Saving Mothers 2011 
- 2013: Sixth Report on Confidential Enquiries into Maternal 
Deaths,[3] there has been a steady increase in the iMMR for cardiac 
disease over the last 4 triennia. The iMMR for cardiac disease in 
2005 - 2007 was 3.73, which has increased to 5.64 during 2008 - 2010 
and to 6.00/100 000 live births in 2011 - 2013.[3] Cardiac disease 
is, therefore, after non-pregnancy-related infections, the second 
most common cause of indirect maternal death. In 2011 - 2013, the 
number of deaths due to peripartum cardiomyopathy was more 
than double that of complications related to rheumatic heart disease 
and formed 34% of the total number of cardiac deaths.
According to the Saving Mothers 2014 - 2016 report,[4] 35% of 
deaths in the medical and surgical disorders category were cardiac 
deaths (35.3%; n=165). The majority of deaths from cardiac 
disease are in the under-30-year age group (58%; n=95). HIV 
was not a significant risk factor, as 63% (n=105) of patients were 
HIV-negative. Sixty percent of maternal deaths occurred after 
delivery (n=99), with 56.6% of patients delivered by caesarean 
section. Thirty-five mothers (85.3%) who died of peripartum 
cardiomyopathy presented with acute symptoms in the postpartum 
period. Forty-four (27%) patients were managed at level 1 hospitals. 
Failure to make a diagnosis, incorrect management and delay in 
referring patients to the appropriate level of care were important 
factors that contributed to avoidable cardiac mortality. 
As our population changes, more women with corrected 
congenital heart defects reach adulthood, and older mothers, 
smokers and obese women with ischaemic heart disease risks 
and rural clients with rheumatic heart disease become pregnant 
and require specialist care. Despite the potential for significant 
maternal morbidity, most patients with cardiac disease can expect 
a satisfactory outcome with careful prepregnancy, antenatal, 
intrapartum and postnatal management. This article aims to assist 
clinicians to identify cardiac clients at risk and reduce avoidable 
mortality.
Risk assessment: Estimation of 
maternal risk
Normal physiological pregnancy-related changes may aggravate 
underlying cardiac disease, leading to associated morbidity and 
mortality. 
To estimate the risk of maternal cardiovascular complications, 
several approaches have been employed. Previously, the complications 
associated with pregnancy in women with heart disease (CARPREG) 
risk score was widely used, but the Task Force of the European Society 
of Cardiology recommends that maternal risk assessment should be 
carried out according to the modified World Health Organization 
(WHO) risk classification.[5] This classification integrates all known 
maternal cardiovascular risk factors, including underlying heart 
disease and any other comorbidities. It includes contraindications for 
pregnancy that are not incorporated in the CARPREG risk scores/
predictors.
The general principles of this classification are depicted in Table 1, and 
a practical application is given in Table 2. For women in WHO class I, 
the risk is very low, and cardiology follow-up during pregnancy may 
be limited to one or two visits. Those in WHO class II are at low or 
moderate risk, and follow-up every trimester is recommended. For 
women in WHO class III, there is a high risk of complications, and 
frequent (monthly or bimonthly) cardiology and obstetric review 
during pregnancy is recommended. Women in WHO class IV 
should be advised against pregnancy but, if they become pregnant 
and refuse termination, monthly or bimonthly review is needed.[6] 
In the context of ‘red-flag’ disorders, patients with WHO class III 
and class IV conditions need continuous expert care and assessment 
throughout pregnancy, whereas all other patients with suspected 
or known cardiac disease in pregnancy require at least one early 
assessment by a combined obstetric and cardiology team to confirm 
a known or suspected diagnosis and to assign risk according to the 
WHO scoring system.
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Rheumatic heart disease
Valvular heart lesions secondary to childhood rheumatic fever are 
important causes of maternal morbidity and mortality in developing 
countries.[7-9] Although many women with valve disease, especially 
less severe valve disease, cope well throughout pregnancy, there 
are some conditions in which the risk of pregnancy is considered 
prohibitive. A red light status should be conferred to pregnant women 
with the following conditions:
• mitral stenosis
• severe mitral regurgitation
• severe aortic stenosis
• baseline New York Heart Association (NYHA) functional class >II
• valve lesions associated with severe left ventricular (LV) dysfunction 
or significant pulmonary hypertension
• valvular disease in women living in low- and middle-income 
countries (LMICs).
Mitral stenosis
Haemodynamic changes in pregnancy, including increases in heart 
rate, cardiac output, red cell mass and plasma volume, can lead to 
increased left atrial pressures and cardiac decompensation. The most 
common complications in pregnancy are a decline in functional 
capacity, atrial arrhythmias, such as atrial fibrillation and pulmonary 
oedema.[10-12] Complications are associated with the severity of the 
stenosis and baseline NYHA functional class.[10,11,13] The Registry of 
Pregnancy and Cardiac Disease (ROPAC) found that the risk of heart 
failure in women with mild, moderate and severe stenosis was 15.8%, 
31.8% and 48.1%, respectively.[14] These data are consistent with those 
in a study of 80 women with rheumatic valve stenosis, which reported 
pulmonary oedema in mild (24%), moderate (34%) and severe (56%) 
cases of mitral stenosis during pregnancy.[15] The degree of stenosis, 
the NYHA class and right ventricular systolic pressure in women 
with mild or moderate stenosis may help to distinguish between 
Table 1. Modified World Health Organization classification of maternal cardiovascular risk: Principles
Risk class Risk of pregnancy by medical condition
I No detectable increased risk of maternal mortality and no/mild increase in morbidity
II Small increased risk of maternal mortality or moderate increase in morbidity
III Significantly increased risk of maternal mortality or severe morbidity. Expert counselling required. If pregnancy is 
decided upon, intensive specialist cardiac and obstetric monitoring is needed throughout pregnancy, childbirth and 
the puerperium
IV Extremely high risk of maternal mortality or severe morbidity; pregnancy contraindicated. If pregnancy occurs, 
termination should be discussed. If pregnancy continues, care as for class III
Table 2. Modified WHO risk stratification
WHO classification I 
Uncomplicated small or mild pulmonary stenosis
Patent ductus arteriosus
Mitral valve prolapse
Successfully repaired simple lesions (atrial or ventricular septal defect, patent ductus arteriosus, anomalous pulmonary venous connection)
WHO classification II (if otherwise well and uncomplicated)
Unrepaired atrial or ventricular septal defect
Unrepaired tetralogy of Fallot
WHO classification II - III (depending on individual)
Mild left ventricular impairment
Native or tissue valvular heart disease not considered WHO class I or class IV
Marfan syndrome without aortic dilation
Aorta <45 mm in association with bicuspid aortic valve disease
Repaired coarctation
WHO classification III
Mechanical valve
Systemic right ventricle
Fontan circulation
Unrepaired cyanotic heart disease 
Other complex congenital heart disease
Aortic dilation 40 - 45 mm in Marfan syndrome
Aortic dilation 45 - 50 mm in bicuspid aortic valve disease
WHO classification IV (pregnancy contraindicated)
Pulmonary arterial hypertension from any cause
Severe systemic ventricular dysfunction (LVEF <30%, NYHA functional class III - IV)
Severe mitral stenosis; severe symptomatic aortic stenosis
Marfan syndrome with aorta dilated >45 mm
Aortic dilation >50 mm in aortic disease associated with bicuspid aortic valve
Native severe coarctation of the aorta
WHO = World Health Organization; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association.
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women who are likely to cope with pregnancy and those at risk of 
complications.[14] The ROPAC study found NYHA class >II to be an 
independent predictor of maternal cardiac events in pregnancy (odds 
ratio (OR) 3.77; 95% confidence interval (CI) 1.93 - 7.38).[14] Heart 
failure (7% v. 49%) and arrhythmic complications (2% v. 21%) are 
more likely to occur in women with NYHA class III or class IV than 
in women with NYHA class I or class II.[16]
The high rate of complications may be reduced with surgical 
intervention and close follow-up during pregnancy and the post-
partum period. A percutaneous balloon mitral commissurotomy 
is effective for selected patients with isolated mitral valve stenosis, 
resulting in a rapid decrease in left atrial pressure and pulmonary 
arterial pressure.[17] Echocardiographic follow-up during pregnancy 
is important to detect early haemodynamic changes that may precede 
and possibly predict clinical deterioration.[14] In the ROPAC study, 30% 
of heart failure cases occurred in the first postpartum week. Therefore, 
during this time, haemodynamic monitoring should include efforts 
to avoid large fluctuations in pre- and after-load. Treatment of heart 
failure should be the same as for non-pregnant women.
Severe mitral regurgitation
Decreases in peripheral vascular resistance and blood pressure 
during pregnancy are believed to physiologically aid women with 
moderate and even severe regurgitation with normal left ventricular 
size and systolic function. However, the increased plasma volume and 
cardiac output may lead to heart failure and arrhythmia in women 
with severe mitral regurgitation, especially those with significant 
ventricular dilatation or dysfunction. In the ROPAC study, severe 
mitral regurgitation was associated with a significant risk of an 
adverse cardiac event in pregnancy (OR 5.25; 95% CI 1.86 - 14.9).[14] 
Severe aortic stenosis
Increased cardiac output in pregnancy in the setting of a restricted 
fixed outflow obstruction is of major importance. Relief of inferior 
vena cava obstruction, autotransfusion from the contracting uterus and 
excessive fluid administration in the postpartum period may also be 
poorly tolerated. Most women with mild or moderate stenosis tolerate 
pregnancy well, while complications such as angina, tachyarrhythmias 
and pulmonary oedema may be seen in women with severe stenosis.[11,18] 
Complication rates of 10 - 42% have been reported.[11,18] Women who 
develop symptoms should be admitted to hospital for bedrest, and 
pulmonary oedema must be treated with diuretics. Aggressive diuresis, 
however, should be avoided as hypovolaemia may cause decreased 
placental perfusion. Percutaneous balloon valvuloplasty should be 
considered for women not responding to medical therapy, provided 
there is no significant regurgitation. 
Valvular disease in women living in low- and middle-
income countries 
The prevalence of rheumatic heart disease in sub-Saharan Africa 
is high, with 2 - 3/1 000 among school-aged children who 
underwent clinical screening and a tenfold higher prevalence if 
echocardiographic screening was added.[19-21] The ROPAC study 
recommended percutaneous balloon mitral commissurotomy as a 
treatment option for young women with moderate or severe mitral 
stenosis who desire pregnancy, even if they are asymptomatic.[14] 
Despite the higher prevalence and more severe forms of mitral 
stenosis in LMICs, valvular interventions are more frequent in 
countries with advanced economies.[9] The problem of delay in 
patients seeking help, financial constraints, lack of information 
about pregnancy risks in women with heart disease and social 
and cultural drawbacks often preclude any appro priate prevention 
strategy in developing countries.[22] Consequently, management of 
patients remains a medical challenge. These factors contribute to 
the high maternal mortality rates in sub-Saharan Africa.[7,22] 
Peripartum cardiomyopathy
Peripartum cardiomyopathy (PPCM) is an idiopathic form of 
cardiomyopathy presenting with heart failure secondary to LV 
dysfunction towards the end of pregnancy or in the months following 
delivery, where no other cause of heart failure is identified.[23] 
Most women present with severe acute heart failure, but even 
those presenting with more subtle symptoms can have long-term 
impaired cardiac function.[24] During 2011 - 2013, PPCM comprised 
34% of cardiac maternal deaths in SA.[7] Forty-eight percent of 
these occurred in the postpartum period and all cases were newly 
diagnosed, as none of the maternal records documented a previous 
history of cardiomyopathy. Delayed diagnosis was an important 
avoidable factor identified by maternal death assessors in this audit. 
All women presenting to the labour ward or emergency unit 
during pregnancy or up to 6 months post partum with symptoms 
of heart failure or shortness of breath should be red flagged. The 
National Committee on Confidential Enquiries into Maternal Deaths 
in SA recommends that clinicians should have a low threshold for 
investigating women presenting with cardiovascular risk factors, 
suspected rheumatic heart disease or symptoms such as shortness 
of breath or chest pain.[25] Appropriate investigations include an 
electrocardiogram (ECG), chest radiograph, echocardiogram and 
computed tomography (CT) pulmonary angiography. Evaluation 
of patients with suspected acute PPCM includes two parts, which 
should be performed simultaneously to allow timely diagnosis and 
treatment: evaluation of cardiopulmonary distress and confirmation 
of the diagnosis. The European Society of Cardiology study group 
on PPCM recommends that the presence of criteria defining 
cardiopulmonary distress should lead to intensive cardiac 
care unit admission: haemodynamic instability (systolic blood 
pressure <90 mmHg, heart rate >130 bpm or <45 bpm), respiratory 
distress (respiratory rate >25/minute, peripheral oxygen saturation <90%), 
or signs of tissue hypoperfusion with abnormal cellular oxygen 
metabolism (increased blood lactate >2.0 mmol/L; low central venous 
oxygen saturation <60 %, if available; altered mental state; cold, clammy, 
mottled skin; oliguria <0.5 mL/kg/h).[26] Echo cardio graphy is used 
to confirm the diagnosis of suspected PPCM, assess concomitant or 
pre-existing cardiac disease, exclude complications such as thrombus 
formation and obtain prognostic information.[26]
Timely diagnosis and treatment are crucial. The management team 
should include cardiologists, intensivists, obstetricians, neonato-
logists and anaesthetists. After initial treatment and stabilisation, the 
patient should be counselled about future risk, impact of subsequent 
pregnancies, duration of medical therapy and contraceptive options. 
The Heart Failure Association PPCM Study Group recommends 
6-monthly follow-up until recovery to a LV ejection fraction 
(LVEF) >50%.[26] In women with LV recovery, who remain stable 
after tapering of heart failure drug therapy, an annual visit is recom-
mended for up to 10 years. There is no consensus as to whether heart 
failure medication should be discontinued in women with recovered 
LV function.
Complications in pregnant women 
with prosthetic heart valves
Pregnant women with mechanical prosthetic heart valves are 
automatically classified as WHO risk category III.[5] This classification 
904       November 2018, Vol. 108, No. 11
CME
implies a significantly increased risk of maternal mortality or 
severe morbidity, necessitating expert counselling regarding the 
maternal and fetal risks of pregnancy. Intensive care is required 
for all women with mechanical prosthetic valves who plan to 
be pregnant despite these risks. Expert care should be a joint 
venture shared between obstetricians skilled in internal medicine 
and cardiologists. The occurrence of pregnancy in a woman with a 
mechanical prosthetic valve should be a red-light event leading to 
early referral to an appropriate level of expert care. Given the scarcity 
of trained cardiologists in SA, this usually implies referral to a large 
metropolitan area with tertiary medical facilities.
In addition to the inherent risk of having a prosthetic valve, 
pregnancy represents a further threat to the wellbeing of women 
with mechanical heart valves: firstly, there is an increased probability 
of valve thrombosis and, secondly, there is an increased risk of 
infection.
Risk of thrombosis
Pregnancy is a procoagulant state with enhanced clot formation 
throughout its duration. The need for this adaptation arises mostly 
in the choriodecidual space, where fibrin deposition is demonstrable. 
The enhanced clotting profile of pregnancy is based on greater 
circulating concentrations of clotting factors, an impeded anticlotting 
mechanism based on activated protein C resistance and inhibition 
of fibrinolysis as a result of placental production of plasminogen 
activator inhibitor (PAI-2). These mechanisms also increase the 
probability of fibrin deposition outside the placental bed, resulting 
in e.g. deep venous thrombosis becoming more common in pregnant 
than non-pregnant women. Mechanical heart valves have an inherent 
risk of thrombosis, which has diminished with the newer generation 
of valves. However, the procoagulant effects of pregnancy may 
increase the risk of valve thrombosis and increase the possibility of 
acute heart failure.
Mechanical valves require anticoagulation regardless of pregnancy. 
Pregnancy may alter the indications for and dose of anticoagulant 
drugs used according to the fetal risks arising from their use and 
the need to allow delivery without an enhanced possibility of 
iatrogenic obstetric haemorrhage caused by the administration 
of these drugs. The possibilities require careful counselling of the 
pregnant woman and her partner before any treatment is changed 
and careful monitoring of the anticoagulant efficacy of any drugs 
subsequently used, as well as a careful strategy for managing the 
parturient needing peripartum anticoagulation. The merits of the 
different drugs available are summarised below:
• Unfractionated heparin (UFH). This must be used intravenously 
according to international guidelines, with studies indicating that 
the subcutaneous use of the drug is associated with a high failure 
rate.[27] The heparin should be titrated against the activated partial 
thromboplastin time, aiming at a ratio of 2.5 - 3.0 compared 
with controls. UFH does not cross the placenta and there is no 
possibility of the baby developing embryopathy when the drug 
is used in the first trimester. UFH is associated with more than 
double the risk of valve thrombosis compared with warfarin 
and a consequential increase in the maternal mortality rate.[28] 
However, the use of UFH obviates any possibility of fetal anomaly 
attributable to oral anticoagulant drugs, although the combined, 
sequential use of UFH followed by warfarin may still result in 
subsequent abortion and fetal wastage.
• Low-molecular-weight heparin (LMWH). This drug is used 
subcutaneously, and when used in the first trimester rather than 
warfarin will avoid the risk of teratogenesis. The dose of LMWH 
needed to reach a therapeutic threshold is increased during 
pregnancy because of the physiological changes. Simultaneously, 
the monitoring of anti-Xa activity is imperative if LMWH is to be 
used.[29] Using LMWH rather than oral anticoagulants is associated 
with a significant increased risk of thromboembolic events, which 
may be as high as 1 in 10.[30] 
• Warfarin. This is the most effective anticoagulant available for the 
prevention of maternal thromboembolic complications. However, 
there is an inherent risk of treatment failure and a background 
maternal mortality risk of 1 in 50. The risk of adverse perinatal 
outcome is much higher, with perinatal wastage as high as 1 in 3. 
The embryopathy risk has been characterised as negligible by 
some guidelines, where the dose of drug used in the first trimester 
is ≤5 mg/day. Evidence in case reports indicates that this is not 
universally true.[31] 
The maternal and fetal risk therefore varies according to the selected 
anticoagulant regimen, and expert counselling together with close 
monitoring are necessary, regardless of the drugs used. Therefore, all 
pregnant women with mechanical heart valves should be accorded 
red-light status when pregnant, with immediate referral to an 
appropriate level of care to choose and optimise the anticoagulant 
regimen.
Risk of haemorrhage
Therapeutic anticoagulation implies an increased risk of 
haemorrhage, especially in obstetric practice, where the possibility 
of life-threatening haemorrhage can and does arise. Haemorrhage 
is a leading direct cause for maternal mortality among SA women 
– a risk that is likely to increase when anticoagulants are used. Data 
from New Zealand indicate that both antepartum and postpartum 
haemorrhage are prevalent: between 1 in 5 and 1 in 7 women 
using LMWH for anticoagulation suffer from a haemorrhagic 
complication, with approximately two-thirds of these complications 
being drug-related.[30] 
These considerations are the second reason to regard all women 
with prosthetic mechanical heart valves as deserving of red-light 
status.
Risk of sepsis
Parturition is associated with an inflammatory cytokine cascade 
and leucocyte infiltration of the fetal tissues.[32] It is a matter of 
speculation that this may represent an adaptive response to incipient 
infection at the time of delivery. However, more apparent is that 
markers of inflammation increase even further in women who have 
premature rupture of the membranes and those who go into preterm 
labour.[33] The risk of sepsis is further underscored by epidemiological 
studies showing the importance of sepsis, unrelated to HIV infection, 
as a cause of maternal mortality in SA.
These considerations must be viewed in the context of infective 
endocarditis that shows a cumulatively increasing incidence over 
time in individuals who have mechanical valves outside of pregnancy. 
There is therefore an inherent risk of infection in and around the 
mechanical valve, which is likely to increase during pregnancy because 
of the prevalence of bacteraemia associated with (vaginal) childbirth. 
The approach to preventing endocarditis owing to parturition is well 
established and is based on the use of routine antibiotic prophylaxis 
during delivery, which is now universally recommended.[34]
What has gone unrecognised, however, are the risks of endocarditis 
related to line sepsis. The use of long-term intravenous lines, where 
UFH is administered intravenously for many days in succession, 
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results in an enhanced risk of sepsis.[35] There is published evidence 
that intravenous catheters are associated with positive cultures in as 
many as 1 in 3 cases where staphyloccoci, enterococci, streptococci 
and Pseudomonas comprise the majority of organisms. Anecdotal 
experience of those providing services to women with prosthetic 
valves confirms instances where line sepsis has been the direct cause 
of endocarditis and has led to maternal mortality.
Modifying red-light status
In patients with mechanical heart valves, their red-light status will 
never change. However, dealing with the red-light level of risk 
requires expert and targeted interventions. These include:
• Prevention of unplanned pregnancy. This responsibility rests with 
all medical practitioners providing care to women with prosthetic 
valves. The use of anticoagulants in this group of women is of 
concern. This is not a barrier to effective contraception and even 
the combined oral contraceptive pill may be used, providing the 
level of anticoagulation is being monitored. Counselling regarding 
family size and offering permanent contraception should always be 
considered in the management of these women.
• Baseline evaluation and establishing a programme of shared care 
between obstetricians and cardiologists are imperative. These patients 
should be seen frequently and should be able to access care rapidly in 
the event of any emergency.
• Choosing an anticoagulant regimen should be deliberately 
considered with informed choice from the pregnant woman 
and her partner. Whatever regimen is implemented, there 
must be facilities for monitoring the efficacy of the drugs used 
(measuring international normalised ratio (INR), activated partial 
thromboplastin time (aPTT) or anti-Xa levels).[36,37] Therapeutic 
levels must be maintained, with the exception of the time spent in 
labour.
• In general, warfarin or LMWH is the preferred option because of 
the risks of line sepsis and social isolation arising from continuous 
hospitalisation.[36]
• Peripartum management should include a scheduled de-escalation 
of long-acting anticoagulant drugs immediately before delivery, 
with short-term bridging using intravenous UFH.
Obstetric procedures should be limited according to their risk of 
sepsis, and prophylactic antibiotics are indicated during labour. 
General measures considered necessary in the intrapartum care 
of pregnant women with heart disease are applicable and include 
nursing the parturient in the semi-Fowler’s position, limiting the use 
of intravenous fluids and providing adequate analgesia during labour.
Conclusion
Cardiac disease in pregnancy is prevalent and an important cause of 
morbidity and mortality. Appropriate management during pregnancy 
requires expert assessment, risk categorisation and ongoing care, 
which may need to include regular follow-up in combined obstetric 
and cardiology clinics. 
Pregnancy also opens a window of opportunity, which may allow 
the identification of undiagnosed subclinical cardiac disease that 
may then be more appropriately and continuously managed to avoid 
morbidity and mortality in later life. 
Summary
• All women with suspected or known cardiac disease should be 
risk assessed early in pregnancy by a combined obstetric and 
cardiology team.
• A percutaneous balloon mitral commissurotomy should be 
considered as a treatment option for young women with moderate 
or severe mitral stenosis.
• The diagnosis of cardiac disease should be suspected in women 
presenting to the labour ward or emergency unit with acute 
shortness of breath during pregnancy or up to 6 months post 
partum.
• All pregnant women with prosthetic heart valves should be 
managed by a combined team consisting of a cardiologist and an 
obstetrician skilled in internal medicine.
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